FLGT Fulgent: Earnings growth forecast for next year
The consensus EPS forecast for the coming year reflects the results of Fulgent Genetics, Inc. (FLGT) pivoting from COVID tests toward oncology diagnostics and subscriptions. The value 19.70 determines the current status of the parameter. Growth is driven by AI platforms that create barriers for partners; however, geopolitics hinder international testing and restrict the supply of essential chemical reagents for laboratories.
Summary analytical data breakdowns for Fulgent Genetics (FLGT)
- price and consensus price forecast:
- company stock capitalization data:
- book capitalization indicators:
- business debt structure and liquidity details:
Total Debt to Capital Fulgent Genetics, Inc.|FLGT - Long-Term Indebtedness to Equity|Short-Term Debt to Capital fulgentgenetics.com|FLGT - Company Cumulative Debt|Debt to Book Capitalization Ratio Fulgent|FLGT - Company Long-Term Indebtedness|Company Current Liabilities Fulgent Genetics|Quick Liquidity Indicator fulgentgenetics.com
- earnings and market ratios statistics:
FLGT - Final Profit|Projected Future Earnings Fulgent Genetics, Inc.|FLGT - Market Cap to Net Income Ratio|Forward P/E Multiple Fulgent|FLGT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fulgent|FLGT - Operating profit before amortization|Net earnings per share (EPS TTM) Fulgent Genetics|FLGT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months fulgentgenetics.com|FLGT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Fulgent Genetics, Inc.
- revenue and sales proceeds data:
Fundamental company analysis:FLGT, Fulgent Genetics
As a portfolio manager, I view this indicator as a leading marker of fundamental value that measures the percentage change in expected earnings per share for the coming year. By analyzing the trend of expected net earnings per share, an investor assesses the sensitivity of Fulgent Genetics, Inc. (FLGT) to macroeconomic shocks, which is critical when diversifying the company's revenue through public and private healthcare contracts.
Competing companies
A (agilent.com) - Earnings growth forecast for next year|DGX - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year ILMN|EXAS - Expected net earnings per share growth next year|Earnings growth forecast for next year RVTY (revvity.com)|Bio-Rad Laboratories (BIO) - Expected net earnings per share growth next year|Anbio Biotechnology - Earnings growth forecast for next year|Expected net earnings per share growth next year soterahealth.com|QDEL: Earnings growth forecast for next year|OPKO Health - Expected earnings per share trend next year|CDNA (CareDx, Inc) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year MRVI|Net earnings per share growth forecast for next year Standard BioTools Inc. (LAB)|CTKB (Cytek Biosciences, Inc.) - Expected earnings per share trend next year|Earnings growth forecast for next year OSUR (OraSure Corp)|Consensus forecast of earnings per share growth for next year Exagen Inc. (XGN)|MDXH: Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year Lucid Diagnostics Inc LUCD|PRE (Prenetics Global Ltd) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Insight Molecular|TRIB (Trinity Biotech) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year PRPH|Earnings growth forecast for next year AIMD|Projected earnings per share increase next year CODX|Net earnings per share growth forecast for next year Heart Test Laboratories HSCS|BMRA: Projected earnings per share growth rate for next year|CDIO - Net earnings per share growth forecast for next year|Onconetix Corp (ONCO) - Expected earnings per share growth for next year|VRAX (Virax Biolabs Group Ltd) - Expected earnings per share growth for next year|Expected net earnings per share growth next year Bluejay Diagnostics Corp (BJDX)|AWH (Aspira Women's Health, Inc.) - Earnings growth forecast for next year|AXDX - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year centogene.com (CNTG)|Consensus forecast of earnings per share growth for next year Enzo Biochem|Consensus forecast of earnings per share growth for next year FRES|Net earnings per one share growth forecast for next year GTG Labs|23andMe Holding Co - Earnings growth forecast for next year|PMD - Earnings growth forecast for next year
